Axillary Approach to Brachial Plexus Blockade Using Ketamine, Regional Versus Intravenous Administration

Administration of Ketamine to Branchial Plexus Block Using Axillary Approach : Comparative Study

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05297422

Enrollment

Registered

2022-03-28

Start date

2022-01-20

Completion date

2023-06-30

Last updated

2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Branchial Plexus Blockade

Keywords

Axillary Approach, Ketamine, Adjuvant

Brief summary

The purpose of this study is to assess Ketamine as an adjuvant to Branchial Plexus Blockade.

Detailed description

After being informed about the study, patients giving written informed consent will undergo anaesthesia using the Ultrasound Guided Axillary Approach to Brachial Plexus Blockade, in order to undergo forearm surgery. The purpose of this study is to assess whether Ketamine as an adjuvant lengthens sensory and motor blockade and whether it has an effect on rebound pain when the anaesthetic effect fades. Therefore the study will compare intravenous, regional and no administration of Ketamine as an adjuvant to Branchial Plexus Blockade. Patients will be asked to fill in a Pain VAS (Visual Analog Scale) for 24 hours following the intervention, in order to assess effectiveness of each anaesthetic method. Side effects, onset time, motor blockade score and rescue dose are also recorded.

Interventions

PROCEDUREForearm surgey

Microsurgery Clinic , KAT Hospital Athens

DRUGRopivacaine

Ropivacaine

DRUGKetamine

Ketamine

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

16 Years to 70 Years

Healthy volunteers

Inclusion criteria

* BMI 20-35 * ASA score I, II, III

Exclusion criteria

* Mental disorder * Peripheral neuropathy * Severe hepatic or renal disease * Gastrointestinal bleeding history

Design outcomes

Primary

Measure	Time frame	Description
VAS (Visual Analog Scale) over 24 hours following intervention	24 hours	VAS scale is expressed in integer numbers ranging from 0-10, where 0=no pain, 10= excruciating pain.

Secondary

Measure	Time frame	Description
Side Effects	24 hours	Dizziness, nausea, vomiting, paraesthesia
Motor Blockade Score	24 hours	0=complete paralysis, 1=partial paralysis, 2=no paralysis
Anesthesia Onset time	24 hours	Time from removal of needle to final motor and sensory blockade result
Rescue Dose	24 hours	Tramadol 100mg intravenously administered only to patients who claim to be in strong pain within the 24 hours after intervention.

Countries

Greece

Contacts

Primary ContactDemetra Solomou

Demetra_Sol@hotmail.com+306987707097

Backup ContactTheodoros Xanthos

theodorosxanthos@yahoo.com+302112136842

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026